Laura Chico
Stock Analyst at Wedbush
(2.08)
# 2,827
Out of 4,734 analysts
199
Total ratings
37.12%
Success rate
-5.91%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RARE Ultragenyx Pharmaceutical | Reiterates: Neutral | $46 → $48 | $41.28 | +16.28% | 12 | Jan 13, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Outperform | $148 | $145.88 | +1.45% | 8 | Dec 16, 2024 | |
| SLDB Solid Biosciences | Initiates: Outperform | $16 | $3.26 | +390.80% | 1 | Dec 13, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $44 → $45 | $27.39 | +64.29% | 9 | Nov 8, 2024 | |
| VIGL Vigil Neuroscience | Maintains: Outperform | $23 → $24 | $2.08 | +1,053.85% | 8 | Nov 8, 2024 | |
| PEPG PepGen | Maintains: Outperform | $19 → $12 | $2.08 | +478.31% | 9 | Nov 8, 2024 | |
| VERA Vera Therapeutics | Maintains: Neutral | $30 → $38 | $33.70 | +12.76% | 7 | Nov 8, 2024 | |
| ANRO Alto Neuroscience | Downgrades: Neutral | $29 → $4 | $4.73 | -15.43% | 3 | Oct 23, 2024 | |
| SAGE Sage Therapeutics | Maintains: Neutral | $9 → $8 | $6.94 | +15.27% | 8 | Oct 9, 2024 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $17 → $25 | $19.46 | +28.47% | 9 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $22 | $3.43 | +541.40% | 1 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $210 → $205 | $140.98 | +45.41% | 16 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $48 | $78.26 | -38.67% | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $7.57 | +190.62% | 8 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $4 | $0.92 | +333.84% | 3 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $41 | $30.13 | +36.08% | 13 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $49 | $38.98 | +25.71% | 8 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $36 | $21.66 | +66.20% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $5.22 | +34.10% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $26 | $23.04 | +12.85% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.91 | +124.03% | 13 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $42 | $18.41 | +128.14% | 7 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $17 | $9.80 | +73.47% | 6 | Jul 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $41 | $2.55 | +1,507.84% | 3 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $31 | $19.12 | +62.13% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $11 | $0.89 | +1,130.43% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $0.70 | +1,045.80% | 1 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.87 | +2.67% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $62.53 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $1.53 | +226.80% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $39.03 | +280.48% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $11.93 | +5,935.21% | 1 | Jan 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $280 | $22.18 | +1,162.40% | 1 | Apr 21, 2017 |
Ultragenyx Pharmaceutical
Jan 13, 2025
Reiterates: Neutral
Price Target: $46 → $48
Current: $41.28
Upside: +16.28%
Neurocrine Biosciences
Dec 16, 2024
Reiterates: Outperform
Price Target: $148
Current: $145.88
Upside: +1.45%
Solid Biosciences
Dec 13, 2024
Initiates: Outperform
Price Target: $16
Current: $3.26
Upside: +390.80%
Edgewise Therapeutics
Nov 8, 2024
Maintains: Outperform
Price Target: $44 → $45
Current: $27.39
Upside: +64.29%
Vigil Neuroscience
Nov 8, 2024
Maintains: Outperform
Price Target: $23 → $24
Current: $2.08
Upside: +1,053.85%
PepGen
Nov 8, 2024
Maintains: Outperform
Price Target: $19 → $12
Current: $2.08
Upside: +478.31%
Vera Therapeutics
Nov 8, 2024
Maintains: Neutral
Price Target: $30 → $38
Current: $33.70
Upside: +12.76%
Alto Neuroscience
Oct 23, 2024
Downgrades: Neutral
Price Target: $29 → $4
Current: $4.73
Upside: -15.43%
Sage Therapeutics
Oct 9, 2024
Maintains: Neutral
Price Target: $9 → $8
Current: $6.94
Upside: +15.27%
Travere Therapeutics
Oct 9, 2024
Maintains: Outperform
Price Target: $17 → $25
Current: $19.46
Upside: +28.47%
Oct 3, 2024
Initiates: Outperform
Price Target: $22
Current: $3.43
Upside: +541.40%
Sep 23, 2024
Maintains: Neutral
Price Target: $210 → $205
Current: $140.98
Upside: +45.41%
Aug 14, 2024
Maintains: Neutral
Price Target: $40 → $48
Current: $78.26
Upside: -38.67%
Aug 13, 2024
Reiterates: Outperform
Price Target: $22
Current: $7.57
Upside: +190.62%
Aug 13, 2024
Reiterates: Outperform
Price Target: $4
Current: $0.92
Upside: +333.84%
Aug 9, 2024
Maintains: Neutral
Price Target: $38 → $41
Current: $30.13
Upside: +36.08%
Aug 9, 2024
Maintains: Outperform
Price Target: $50 → $49
Current: $38.98
Upside: +25.71%
Aug 9, 2024
Maintains: Outperform
Price Target: $38 → $36
Current: $21.66
Upside: +66.20%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $5.22
Upside: +34.10%
Aug 2, 2024
Maintains: Outperform
Price Target: $30 → $26
Current: $23.04
Upside: +12.85%
Aug 2, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.91
Upside: +124.03%
Jul 29, 2024
Reiterates: Outperform
Price Target: $42
Current: $18.41
Upside: +128.14%
Jul 11, 2024
Reiterates: Outperform
Price Target: $17
Current: $9.80
Upside: +73.47%
Jun 6, 2024
Reiterates: Outperform
Price Target: $41
Current: $2.55
Upside: +1,507.84%
May 9, 2024
Maintains: Outperform
Price Target: $35 → $31
Current: $19.12
Upside: +62.13%
Apr 11, 2024
Maintains: Outperform
Price Target: $13 → $11
Current: $0.89
Upside: +1,130.43%
Apr 5, 2024
Initiates: Outperform
Price Target: $8
Current: $0.70
Upside: +1,045.80%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.87
Upside: +2.67%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $62.53
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $1.53
Upside: +226.80%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $39.03
Upside: +280.48%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $11.93
Upside: +5,935.21%
Apr 21, 2017
Initiates: Strong Buy
Price Target: $280
Current: $22.18
Upside: +1,162.40%